Poster exhibition
Vaccines

Programm

• • Poster
  • P 289

  Optimized antigen design enhances immunogenicity of measles vaccine-derived COVID-19 vaccines

  • Mona V. Lange (Langen / DE)

   SARS-CoV-2, Vaccines
• • Poster
  • P 290

  A non-transmissible live attenuated SARS-CoV-2 vaccine

  • Julia M. Adler (Berlin / DE)

   Vaccines
• • Poster
  • P 291

  The pragmatic, multi-center, three-arm, partially randomized HEVACC trial – heterologous SARS-CoV-2 vaccination with ChAdOx-1 and BNT162b2

  • Dr. Janine Kimpel (Innsbruck / AT)

   Vaccines
• • Poster
  • P 292

  Understanding the factors determining the fate of HBV-specific CD8 T cells elicited by therapeutic vaccination in low- and high-titer HBV infection

  • Edanur Ates Öz (Munich / DE)

   Adaptive immunity, Vaccines
• • Poster
  • P 293

  Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity

  • Christian Meyer zu Natrup (Hannover / DE)

   Adaptive immunity, Vaccines
• • Poster
  • P 294

  Formulation and evaluation of the anticancer potential of CD44 targeted Oncolytic Measles Virus (OMV) nanoformulation in prostate cancer xenograft model – a multi-dynamic approach for advanced virotherapeutic moiety

  • Dr. Tahir Ahmad (Islamabad / PK)

   Antiviral therapy and resistance, Vaccines
• • Poster
  • P 295

  Adenovirus type 34 and HVR1-deleted Adenovirus type 5 do not bind to PF4 – clearing the path towards vectors without thrombosis risk

  • Nissai Beaude (Witten / DE)

   Vaccines, Viral vectors and gene therapy
• • Poster
  • P 296

  Spotting immunity – analysis of cell mediated protection after VZV vaccination

  • Kevin Strecker (Strassberg / DE)

   Adaptive immunity, Vaccines
• • Poster
  • P 297

  Hamster model of severe COVID-19 demonstrates differential efficacy of licensed vaccines in the absence of immunopathogenesis

  • Dr. Aileen Ebenig (Langen / DE)

   SARS-CoV-2, Vaccines
• • Poster
  • P 298

  Breakthrough infection with Omicron variants induces persistent and broadly cross-reactive adaptive immunity and associates with protection from reinfection

  • PD Dr. Christof Geldmacher (Munich / DE)

   SARS-CoV-2, Vaccines
• • Poster
  • P 299

  Ex vivo characterization of IE-1/pp65-expressing adenoviral vectors as potential T cell vaccine candidates for human Cytomegalvirus

  • David Brenner (Regensburg / DE)

   Adaptive immunity, Vaccines
• • Poster
  • P 300

  Glycoprotein K8.1 as a target for Kaposi's sarcoma-associated Herpesvirus vaccine development

  • Hannah Byren (Erlangen / DE)

   Adaptive immunity, Vaccines
• • Poster
  • P 301

  The relationship between sleep quality and the immunogenicity of COVID-19 vaccinations

  • Isabell Wagenhäuser (Wuerzburg / DE)

   Vaccines
• • Poster
  • P 303

  Imvanex vaccination induces immune responses against monkeypox virus and likely contributes to the prevention of future outbreaks

  • Dr. Luca M. Zaeck (Rotterdam / NL)

   Emerging viruses and zoonosis, Vaccines
• • Poster
  • P 305

  RCMV ∆E27 as a potential live attenuated vaccine in rat kidney transplantation model

  • Dr. Anna Malyshkina (Essen / DE)

   Adaptive immunity, Vaccines
• • Poster
  • P 306

  Oropharyngeal spray application of the Jcovden® vaccine induces mucosal immunity in Comirnaty® primed mice

  • Vera Viherlehto (Erlangen / DE)

   Vaccines
• • Poster
  • P 307

  Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination

  • Tanya Dogra (Magdeburg / DE)

   Vaccines
• • Poster
  • P 308

  Broad neutralization against contemporary and antigenically-distant respiratory syncytial virus (RSV) strains elicited by the vaccine candidate RSVPreF3-AS01

  • Dr. Sandro Halwe (Frankfurt / DE)

   Host cell factors and modulation, Vaccines
• • Poster
  • P 309

  Respiratory Syncytial Virus (RSV) prefusion F protein candidate vaccine (RSVPreF3 OA) is efficacious in adults ≥ 60 years of age (YOA)

  • Dr. Young-In Ko (Munich / DE)

   Clinical virology, Vaccines
• • Poster
  • P 310

  Generation and characterization of an Adenoviral vaccine candidate expressing the pentameric complex of human cytomegalovirus

  • Franz Attenkofer (Regensburg / DE)

   Adaptive immunity, Vaccines
• • Poster
  • P 311

  Vaccine to inhibit autochthonous transmission of Hepatitis E (VaccinATE)

  • Dr. Elmira Aliabadi (Hannover / DE)

   Adaptive immunity, Vaccines
• • Poster
  • P 312

  In vitro characterization of three MVA based candidate vaccines expressing SARS-CoV-2 envelope, ORF3a and membrane proteins

  • Dr. Satyendra Kumar (Munich / DE)

   Vaccines
• • Poster
  • P 313

  In vitro characterization of two MVA candidate vaccines expressing the fusion and matrix proteins of Nipah virus

  • Dr. Georgia Kalodimou (Munich / DE)

   Emerging viruses and zoonosis, Vaccines
• • Poster
  • P 314

  Requirements for heterologous T cell help against HIV-1 in humans

  • Dominik Damm (Erlangen / DE)

   Adaptive immunity, Vaccines
• • Poster
  • P 315

  Targeted downregulation of Modified Vaccinia Virus Ankara (MVA)-driven transgene expression by cellular microRNAs

  • Dr. Marc Schweneker (Martinsried / DE)

   Vaccines, Viral vectors and gene therapy
• • Poster
  • P 316

  Impact of heterologous MVA-booster vaccination on SARS-CoV-2 specific immune responses in a Golden Syrian Hamster model for Coronavirus disease 2019 (COVID-19)

  • Dr. Lisa-Marie Schünemann (Hannover / DE)

   Adaptive immunity, Vaccines
• • Poster
  • P 317

  Generation and in vitro characterization of two recombinant MVA candidate vaccines expressing Marburg virus glycoprotein and nucleoprotein

  • Dr. Alina Tscherne (Munich / DE)

   Emerging viruses and zoonosis, Vaccines
• • Poster
  • P 318

  Surface expression of an immunogenic epitope of Foot-and-Mouth Disease virus in a Pseudorabies virus live attenuated vaccine by insertion into the essential envelope glycoprotein gB

  • Dr. Walter Fuchs (Greifswald / DE)

   Vaccines, Virus receptors and entry
• • Poster
  • P 319

  Recombinant anti-Bunyavirus vaccine candidates based on live-attenuated Measles virus

  • Dr. Mohamed Rasheed Gadalla (Langen / DE)

   Emerging viruses and zoonosis, Vaccines